Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
J Nephrol ; 30(5): 645-652, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28831679

ABSTRACT

Patients with chronic kidney disease (CKD) are at increased risk of fractures. The fracture risk steadily increases along with the progression of renal disease to become several-fold higher in end-stage renal disease (ESRD) patients as compared to age and sex-matched controls. Renal osteodystrophy (ROD) is a heterogeneous group of metabolic bone diseases complicating progressive chronic kidney disease. Bone biomarkers and bone imaging techniques may help to assess bone health and predict fractures in CKD, but do have important inherent limitations. The gold standard for the diagnosis and specific classification of renal osteodystrophy (ROD) remains the (quantitative) histomorphometric analysis of the bone biopsy. By informing on bone turnover and mineralization, a bone biopsy may help guide prevention and treatment of ROD and its consequences. This review aims to present an update on epidemiological and procedural aspects, clinical indications, and histomorphometric analysis of bone biopsies and to define the role of bone biopsy in current CKD-MBD care.


Subject(s)
Biopsy/methods , Bone and Bones/pathology , Chronic Kidney Disease-Mineral and Bone Disorder/pathology , Chronic Kidney Disease-Mineral and Bone Disorder/physiopathology , Renal Insufficiency, Chronic/complications , Bone Remodeling , Calcification, Physiologic , Chronic Kidney Disease-Mineral and Bone Disorder/diagnosis , Chronic Kidney Disease-Mineral and Bone Disorder/epidemiology , Humans , Patient Selection
2.
Osteoporos Int ; 27(2): 489-97, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26294291

ABSTRACT

UNLABELLED: Bone loss and vascular calcification coincide in patients with end-stage renal disease, similar as to what is observed in the general population. In the present bone biopsy study, we provide further evidence that (micro-)inflammation may represent a common soil for both diseases. INTRODUCTION: Vascular calcification is a common complication of end-stage renal disease (ESRD) and is predictive of subsequent cardiovascular disease and mortality. Mounting evidence linking bone disorders with vascular calcification has contributed to the development of the concept of the bone-vascular axis. Inflammation is involved in the pathogenesis of both disorders. The aim of the present study was to evaluate the relationship between aortic calcification, inflammation, and bone histomorphometry in patients with ESRD. METHODS: Parameters of inflammation and mineral metabolism were assessed in 81 ESRD patients (55 ± 13 year, 68 % male) referred for renal transplantation. Static bone histomorphometry parameters were determined on transiliac bone biopsies performed during the transplant procedure. Aortic calcification was quantified on lateral lumbar X-rays using the Kauppila method. RESULTS: Aortic calcification, low bone turnover, and low bone area were observed in 53, 37, and 21 % of patients respectively. Inflammatory markers were found to be independently associated with aortic calcification (hsIL-6) and low bone area (TNF-α). Low bone area associated with aortic calcification, independent of age, diabetes, and inflammation. CONCLUSIONS: Low bone area and inflammation associates with aortic calcification, independent of each other and traditional risk factors. Our data emphasize the role of (micro-)inflammation in the bone-vascular axis in CKD.


Subject(s)
Aortic Diseases/etiology , Inflammation/complications , Kidney Failure, Chronic/complications , Osteoporosis/etiology , Vascular Calcification/etiology , Adult , Aged , Biopsy , Bone Remodeling/physiology , Female , Humans , Ilium/pathology , Inflammation/physiopathology , Inflammation Mediators/metabolism , Kidney Failure, Chronic/physiopathology , Kidney Failure, Chronic/surgery , Kidney Transplantation , Male , Middle Aged , Osteoporosis/pathology , Osteoporosis/physiopathology
3.
Kidney Int ; 71(4): 298-303, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17149373

ABSTRACT

In the present study, we characterized and compared the mineral phase deposited in the aortic wall of two different frequently used chronic renal failure rat models of vascular calcification. Vascular calcification was induced in rats by either a 4-week adenine treatment followed by a 10-week high-phosphate diet or 5/6 nephrectomy followed by 6 weeks of 0.25 microg/kg/day calcitriol treatment and a high-phosphate diet. Multi-element mapping for calcium and phosphate together with mineral identification was performed on several regions of aortic sections by means of synchrotron X-ray-mu-fluorescence and diffraction. Bulk calcium and magnesium content of the aorta was assessed using flame atomic absorption spectrometry. Based on the diffraction data the Von Kossa-positive precipitate in the aortic regions (N=38) could be classified into three groups: (1) amorphous precipitate (absence of any diffraction peak pattern, N=12); (2) apatite (N=16); (3) a combination of apatite and magnesium-containing whitlockite (N=10). The occurrence of these precipitates differed significantly between the two models. Furthermore, the combination of apatite and whitlockite was exclusively found in the calcitriol-treated animals. These data indicate that in adenine/phosphate-induced uremia-related vascular calcification, apatite is the main component of the mineral phase. The presence of magnesium-containing whitlockite found in addition to apatite in the vitamin D-treated rats, has to be seen in view of the well-known vitamin D-stimulated gastrointestinal absorption of magnesium.


Subject(s)
Apatites/metabolism , Calcinosis/metabolism , Renal Insufficiency/complications , Uremia/complications , Vascular Diseases/metabolism , Animals , Aorta/metabolism , Calcinosis/drug therapy , Calcinosis/etiology , Calcitriol/therapeutic use , Calcium Channel Agonists/therapeutic use , Male , Rats , Rats, Sprague-Dawley , Rats, Wistar , Renal Insufficiency/metabolism , Spectrometry, X-Ray Emission , Uremia/metabolism , Vascular Diseases/drug therapy , Vascular Diseases/etiology , X-Ray Diffraction
4.
Calcif Tissue Int ; 78(4): 227-32, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16604283

ABSTRACT

Silicon (Si) deficiency in animals results in bone defects. Choline-stabilized orthosilicic acid (ch-OSA) was found to have a high bioavailability compared to other Si supplements. The effect of ch-OSA supplementation was investigated on bone loss in aged ovariectomized (OVX) rats. Female Wistar rats (n = 58, age 9 months) were randomized in three groups. One group was sham-operated (sham, n = 21), and bilateral OVX was performed in the other two groups. OVX rats were supplemented orally with ch-OSA over 30 weeks (OVX1, n = 20; 1 mg Si/kg body weight daily) or used as controls (OVX0, n = 17). The serum Si concentration and the 24-hour urinary Si excretion of supplemented OVX rats was significantly higher compared to sham and OVX controls. Supplementation with ch-OSA significantly but partially reversed the decrease in Ca excretion, which was observed after OVX. The increase in bone turnover in OVX rats tended to be reduced by ch-OSA supplementation. ch-OSA supplementation increased significantly the femoral bone mineral content (BMC) in the distal region and total femoral BMC in OVX rats, whereas lumbar BMC was marginally increased. Femoral BMD was significantly increased at two sites in the distal region in OVX rats supplemented with ch-OSA compared to OVX controls. Total lumbar bone mineral density was marginally increased by ch-OSA supplementation. In conclusion, ch-OSA supplementation partially prevents femoral bone loss in the aged OVX rat model.


Subject(s)
Aging , Dietary Supplements , Femur/drug effects , Osteoporosis/diet therapy , Osteoporosis/prevention & control , Silicic Acid/therapeutic use , Absorptiometry, Photon , Animals , Bone Density/drug effects , Calcium/urine , Choline , Female , Femur/physiology , Lumbar Vertebrae/drug effects , Lumbar Vertebrae/physiology , Ovariectomy , Rats , Rats, Wistar , Silicic Acid/analysis , Silicic Acid/chemistry
5.
Calcif Tissue Int ; 75(5): 405-15, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15592797

ABSTRACT

In a previous experimental study using a chronic renal failure rat model, a dose-related multiphasic effect of strontium (Sr) on bone formation was found that could be reproduced in an in vitro set-up using primary rat osteoblasts. The results from the latter study allowed us to distinguish between a reduced nodule formation in the presence of an intact mineralization at low Sr-doses (1 microg/ml) and an interference of the element with the hydroxyapatite (HA) formation at high doses (20-100 microg/ml). To further investigate the latter effect of Sr on physicochemical bone mineral properties, an in vitro study was set up in which the UMR-106 rat osteosarcoma cell line was exposed to Sr, added to the cell culture medium in a concentration range varying between 0-100 microg/ml. Temporal growth and functionality of the culture was investigated by measurement of the alkaline phosphatase activity and calcium (Ca) concentration in the culture medium (used as an index of Ca-incorporation, i.e., HA formation) at various time points. At the end of the culture period (14 days post-confluence), samples of the mineralized cultures were taken for further analysis using X-ray diffraction (XRD) and Fourier Transform Infra-Red Spectroscopy (FTIR). Synthetic HA doped with various Sr concentrations (based on the cell culture and previous experimental studies and yielding Sr/(Sr + Ca) ratios ranging from 0-60%), was prepared and examined for crystal growth and solubility. Crystal size was assessed using scanning electron microscopy (SEM). Ca incorporation indicated a reduced mineralization in the 20 and 100 microg/ml Sr groups vs. controls. Sr-doped synthetic HA showed a significant dose-dependent reduction in crystal growth, as assessed by SEM, and an increase in solubility, apparent from 12.7% Sr/(Sr + Ca) on. Moreover, in both mineralized cultures and synthetic HA, XRD and FTIR analysis showed a reduced crystallinity and altered crystal lattice at similar concentrations. These new data support our previous in vivo and in vitro findings and point to a potential physicochemical interference of Sr with HA formation and crystal properties in vivo.


Subject(s)
Calcification, Physiologic/drug effects , Durapatite/chemistry , Strontium/pharmacology , Alkaline Phosphatase/drug effects , Animals , Calcium/analysis , Calcium/metabolism , Cell Line, Tumor , Crystallization , Culture Media/analysis , Dose-Response Relationship, Drug , Microscopy, Electron, Scanning , Osteoblasts/drug effects , Osteoblasts/metabolism , Rats , Solubility/drug effects , Spectroscopy, Fourier Transform Infrared , Time Factors , X-Ray Diffraction
6.
Ren Fail ; 21(3-4): 409-12, 1999.
Article in English | MEDLINE | ID: mdl-10416220

ABSTRACT

The study of urinary proteins is an important tool in the screening and diagnosis of patients with renal impairment. Quantification of total proteins, although useful, can provide only limited information. Gel electrophoresis of urine samples may provide more detailed information.


Subject(s)
Electrophoresis, Polyacrylamide Gel/standards , Kidney Diseases/diagnosis , Proteinuria/urine , Humans , Image Processing, Computer-Assisted , Sensitivity and Specificity , Silver Staining
7.
Kidney Int Suppl ; 73: S70-6, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10633468

ABSTRACT

Renal failure inevitably leads to metabolic bone disease. Low turnover disease or adynamic bone disease (ABD) is characterized by a low number of osteoblasts with normal or reduced numbers of osteoclasts. Mineralization proceeds at a normal rate, resulting in normal or decreased osteoid thickness. Recently, it became clear that the relative contribution of the various types of renal osteodystrophy (ROD) to the spectrum of the histologic picture in renal failure patients underwent profound changes during the last 25 years. At the moment, the exact physiopathological mechanisms behind ABD are not yet elucidated, and thus the reason(s) for its increasing prevalence remains poorly understood. A number of epidemiological and experimental data suggest a multifactorial pathophysiologic process, in which hypoparathyroidism and suppression of the osteoblast are the main actors. Compared to adynamic bone disease, osteomalacia has now become a much rarer disease (around 4%), at least in Western countries. On the other hand, recent studies indicate that this particular bone disease entity might still regularly occur in less developed countries. Osteomalacia originates from a direct effect on the mineralization process. With this type of renal bone disease, the effects of secondary hyperparathyroidism on bone are overridden by a number of metabolic abnormalities that finally result in a defective bone mineralization, as occurs, for instance, when the lag time between osteoid deposition and its mineralization is increased. The relationship between exogenous and endogenous vitamin D deficiency (mainly calcitriol) and the histologic finding of osteomalacia in uremic patients is well known. Recent data showed distinctly lowered 25-(OH) vitamin D3 levels in the presence of unaffected calcitriol concentrations in patients with osteomalacic lesions, as assessed radiologically by the presence of Looser's zones. Recently, we found that bone strontium levels were increased in patients with osteomalacia as compared to all other types of ROD. Strontium accumulation appeared to originate mainly from the use of strontium-contaminated dialysate, which resulted from the addition of strontium-containing acetate-based concentrates. Evidence for a causal role of the element in the development of a mineralization defect could be tested experimentally by adding strontium to drinking water in a chronic renal failure rat model.


Subject(s)
Bone Diseases, Metabolic/etiology , Chronic Kidney Disease-Mineral and Bone Disorder/etiology , Renal Insufficiency/complications , Animals , Humans , Hyperparathyroidism/etiology , Osteoblasts/physiology , Osteomalacia/etiology , Parathyroid Hormone/blood , Rats
SELECTION OF CITATIONS
SEARCH DETAIL
...